Literature DB >> 23275103

Risk factors associated with pediatric intensive care unit admission and mortality after pediatric stem cell transplant: possible role of renal involvement.

Nabil E Hassan1, Aly S Mageed, Dominic J Sanfilippo, Dianne Reischman, Ulrich A Duffner, Surender Rajasekaran.   

Abstract

BACKGROUND: Hematopoietic stem-cell transplant (HSCT) is associated with many risk factors for life-threatening complications. Post-transplant critical illness often requires admission to the pediatric intensive care unit (PICU).
METHODS: A retrospective analysis was made on the risk factors associated with PICU admission and mortality of all HSCT patients at Helen DeVos Children's Hospital from October 1998 to November 2008.
RESULTS: One hundred and twenty-four patients underwent HSCT, with 19 (15.3%) requiring 29 PICU admissions. Fifty patients received autologous, 38 matched sibling, and 36 matched un-related donor HSCT, with 10%, 13% and 25% of these patients requiring PICU admission, respectively (P=0.01). Among the HSCT patients, those who were admitted to the PICU were more likely to have renal involvement by either malignancy requiring nephrectomy or a post transplant complication increasing the likelihood of decreased renal function (21.1% vs. 4.8%, P=0.03). PICU admissions were also more likely to receive pre-transplant total body irradiation (52.6% vs. 27.6%, P=0.03). Among 29 patients with PICU admission, 3 died on day 1 after admission, and 5 within 30 days (a mortality rate of 17%). Thirty days after PICU admission, non-survivors had a higher incidence of respiratory failure and septic shock on admission compared with survivors (80% vs. 16.7%, P=0.01 and 80% vs. 4.2%, respectively, P=0.001). Two survivors with chronic renal failure underwent renal transplantation successfully.
CONCLUSIONS: Total body irradiation and renal involvement are associated with higher risk for PICU admissions after HSCT in pediatric patients, while septic shock upon admission and post-admission respiratory failure are associated with mortality.

Entities:  

Mesh:

Year:  2012        PMID: 23275103     DOI: 10.1007/s12519-012-0391-z

Source DB:  PubMed          Journal:  World J Pediatr            Impact factor:   2.764


  22 in total

Review 1.  Late complications after hematopoietic stem cell transplantation.

Authors:  André Tichelli; Alicia Rovó; Jakob Passweg; Carl Philipp Schwarze; Maria Teresa Van Lint; Mutlu Arat; Gérard Socié
Journal:  Expert Rev Hematol       Date:  2009-10       Impact factor: 2.929

2.  Chronic lymphocytic leukemia can cause acute renal failure even in early stage patients.

Authors:  Claire Lentaigne; Clare Craig; Kate Cwynarski; Archie Prentice; Christopher McNamara
Journal:  Leuk Lymphoma       Date:  2010-02

3.  Introduction of the oncological pediatric risk of mortality score (O-PRISM) for ICU support following stem cell transplantation in children.

Authors:  D T Schneider; P Lemburg; I Sprock; R Heying; U Göbel; W Nürnberger
Journal:  Bone Marrow Transplant       Date:  2000-05       Impact factor: 5.483

Review 4.  Evolving use of biomarkers for kidney injury in acute care settings.

Authors:  Elliot Ho; Arrash Fard; Alan Maisel
Journal:  Curr Opin Crit Care       Date:  2010-10       Impact factor: 3.687

5.  Unrelated cord blood transplantation can restore hematologic and immunologic functions in patients with Chediak-Higashi syndrome.

Authors:  Rawad Rihani; Maha Barbar; Nesreen Faqih; Hadeel Halalsheh; Ayad Ahmad Hussein; Abdul Hadi Al-Zaben; Fawzi Abdel Rahman; Mahmoud Sarhan
Journal:  Pediatr Transplant       Date:  2011-03-30

6.  Renal involvement of non-Hodgkin's lymphoma and its prognostic effect in childhood.

Authors:  Munevver Buyukpamukçu; Ali Varan; Burça Aydin; Gulsev Kale; Deniz Akata; Bilgehan Yalçin; Canan Akyuz; Tezer Kutluk
Journal:  Nephron Clin Pract       Date:  2005-04-11

7.  A simple estimate of glomerular filtration rate in adolescent boys.

Authors:  G J Schwartz; B Gauthier
Journal:  J Pediatr       Date:  1985-03       Impact factor: 4.406

8.  Survival in a recent cohort of mechanically ventilated pediatric allogeneic hematopoietic stem cell transplantation recipients.

Authors:  Josephus P J van Gestel; Casper W Bollen; Marc B Bierings; Jaap Jan Boelens; Nico M Wulffraat; Adrianus J van Vught
Journal:  Biol Blood Marrow Transplant       Date:  2008-12       Impact factor: 5.742

9.  Haemopoietic stem cell transplantation for children in Australia and New Zealand, 1998-2006: a report on behalf of the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group.

Authors:  Andrew S Moore; Peter J Shaw; Andrew R Hallahan; Tina L Carter; Tatjana Kilo; Ian Nivison-Smith; Tracey A O'Brien; Heather Tapp; Lochie Teague; Shaun R Wilson; Karin Tiedemann
Journal:  Med J Aust       Date:  2009-02-02       Impact factor: 7.738

10.  Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research.

Authors:  M R Bishop; B R Logan; S Gandham; B J Bolwell; J-Y Cahn; H M Lazarus; M R Litzow; D I Marks; P H Wiernik; P L McCarthy; J A Russell; C B Miller; J Sierra; G Milone; A Keating; F R Loberiza; S Giralt; M M Horowitz; D J Weisdorf
Journal:  Bone Marrow Transplant       Date:  2007-12-17       Impact factor: 5.483

View more
  2 in total

1.  Risk factors for ICU admission and ICU survival after allogeneic hematopoietic SCT.

Authors:  R Benz; U Schanz; M Maggiorini; J D Seebach; G Stussi
Journal:  Bone Marrow Transplant       Date:  2013-09-23       Impact factor: 5.483

2.  Experience from a single paediatric transplant centre with identification of some protective and risk factors concerning the development of hepatic veno-occlusive disease in children after allogeneic hematopoietic stem cell transplant.

Authors:  N Maximova; G Ferrara; M Minute; A Pizzol; V Kiren; M Montico; M Gregori; P Tamaro
Journal:  Int J Hematol       Date:  2014-04-09       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.